Metabolic brain networks in translational neurology: Concepts and applications

Annals of Neurology

Volumn 72, Issue 5, 2012, Pages 635-647

  Niethammer, Martin ^a   Eidelberg, David ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; LEVODOPA;

ALGORITHM; ARTICLE; BRAIN BLOOD FLOW; BRAIN MAPPING; BRAIN REGION; COGNITION; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GLUCOSE METABOLISM; HUMAN; METABOLIC BRAIN NETWORK; NEUROLOGY; NEUROMODULATION; NEUROPHYSIOLOGY; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RIGIDITY; SUBTHALAMIC NUCLEUS; TRANSLATIONAL RESEARCH; UNIFIED PARKINSON DISEASE RATING SCALE;

BRAIN; BRAIN MAPPING; HUMANS; METABOLIC NETWORKS AND PATHWAYS; NERVOUS SYSTEM DISEASES; NEUROLOGY;

EID: 84871945993     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23631     Document Type: Article

References (82)

1. Seeley WW, Menon V, Schatzberg AF, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci 2007; 27: 2349-2356. (Pubitemid 46340968)
2. Smith SM, Miller KL, Salimi-Khorshidi G, et al. Network modelling methods for FMRI. Neuroimage 2011; 54: 875-891.
3. Habeck C, Stern Y,. Multivariate data analysis for neuroimaging data: overview and application to Alzheimer's disease. Cell Biochem Biophys 2010; 58: 53-67.
4. Eidelberg D,. Metabolic brain networks in neurodegenerative disorders: A functional imaging approach. Trends Neurosci 2009; 32: 548-557.
5. Habeck C, Foster NL, Perneczky R, et al. Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. Neuroimage 2008; 40: 1503-1515.
6. Asllani I, Habeck C, Scarmeas N, et al. Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer's disease. J Cereb Blood Flow Metab 2008; 28: 725-736. (Pubitemid 351432785)
7. Feigin A, Tang C, Ma Y, et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 2007; 130 (pt 11): 2858-2867. (Pubitemid 350033965)
8. Eidelberg D, Surmeier DJ,. Brain networks in Huntington disease. J Clin Invest 2011; 121: 484-492.
9. Pourfar M, Feigin A, Tang CC, et al. Abnormal metabolic brain networks in Tourette syndrome. Neurology 2011; 76: 944-952.
10. Niethammer M, Carbon M, Argyelan M, Eidelberg D,. Hereditary dystonia as a neurodevelopmental circuit disorder: evidence from neuroimaging. Neurobiol Dis 2011; 42: 202-209.
11. Wu T, Wang L, Hallett M, et al. Effective connectivity of brain networks during self-initiated movement in Parkinson's disease. Neuroimage 2011; 55: 204-215.
12. Poston KL, Eidelberg D,. Functional brain networks and abnormal connectivity in the movement disorders. Neuroimage 2011 Dec 21 [Epub ahead of print].
13. Moeller JR, Strother SC,. A regional covariance approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab 1991; 11: A121-A135.
14. Spetsieris PG, Eidelberg D,. Scaled subprofile modeling of resting state imaging data in Parkinson's disease: methodological issues. Neuroimage 2011; 54: 2899-2914.
15. Crow EL, Shimizu K, eds. Lognormal distributions: Theory and applications. New York, NY: Dekker, 1988.
16. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007; 130 (pt 7): 1834-1846. (Pubitemid 47343798)
17. Tang CC, Poston KL, Dhawan V, Eidelberg D,. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci 2010; 30: 1049-1056.
18. Feigin A, Kaplitt MG, Tang C, et al. Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A 2007; 104: 19559-19564.
19. Mure H, Hirano S, Tang CC, et al. Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects. Neuroimage 2011; 54: 1244-1253.
20. Moeller JR, Nakamura T, Mentis MJ, et al. Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 1999; 40: 1264-1269. (Pubitemid 29385633)
21. Eckert T, Tang C, Eidelberg D,. Assessment of the progression of Parkinson's disease: A metabolic network approach. Lancet Neurol 2007; 6: 926-932. (Pubitemid 47405003)
22. Lin TP, Carbon M, Tang C, et al. Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain 2008; 131 (pt 5): 1373-1380.
23. Ma Y, Tang C, Spetsieris P, et al. Abnormal metabolic network activity in Parkinson's disease: Test-retest reproducibility. J Cereb Blood Flow Metab 2007; 27: 597-605.
24. Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: A metabolic imaging study using pattern analysis. Lancet Neurol 2010; 9: 149-158.
25. Ma Y, Peng S, Spetsieris PG, et al. Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism. J Cereb Blood Flow Metab 2012; 32: 633-642.
26. DeLong MR, Wichmann T,. Circuits and circuit disorders of the basal ganglia. Arch Neurol 2007; 64: 20-24. (Pubitemid 46072419)
27. Ma Y, Eidelberg D,. Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease. Mol Imaging Biol 2007; 9: 223-233. (Pubitemid 47028738)
28. Hirano S, Asanuma K, Ma Y, et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J Neurosci 2008; 28: 4201-4209.
29. Eckert T, Van Laere K, Tang C, et al. Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 2007; 34: 496-501. (Pubitemid 46426989)
30. Feigin A, Antonini A, Fukuda M, et al. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 2002; 17: 1265-1270. (Pubitemid 36041340)
31. Ma Y, Huang C, Dyke JP, et al. Parkinson's disease spatial covariance pattern: noninvasive quantification with perfusion MRI. J Cereb Blood Flow Metab 2010; 30: 505-509.
32. Melzer TR, Watts R, MacAskill MR, et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. Brain 2011; 134 (pt 3): 845-855.
33. Wu T, Long X, Zang Y, et al. Regional homogeneity changes in patients with Parkinson's disease. Hum Brain Mapp 2009; 30: 1502-1510.
34. Skidmore F, Spetsieris P, Yang M, et al, eds. Diagnosis of Parkinson's disease using resting state fMRI. 15th International congress of Parkinson's disease and movement disorders. 2011: LB22.
35. Eidelberg D, Moeller JR, Ishikawa T, et al. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. J Nucl Med 1995; 36: 378-383.
36. Lozza C, Baron JC, Eidelberg D, et al. Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp 2004; 22: 236-245. (Pubitemid 38891002)
37. Asanuma K, Tang C, Ma Y, et al. Network modulation in the treatment of Parkinson's disease. Brain 2006; 129 (pt 10): 2667-2678. (Pubitemid 44522100)
38. Antonini A, Moeller JR, Nakamura T, et al. The metabolic anatomy of tremor in Parkinson's disease. Neurology 1998; 51: 803-810. (Pubitemid 28449263)
39. Isaias IU, Marotta G, Hirano S, et al. Imaging essential tremor. Mov Disord 2010; 25: 679-686.
40. Eidelberg D, Moeller JR, Kazumata K, et al. Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain 1997; 120 (pt 8): 1315-1324. (Pubitemid 27344702)
41. Parent A, Hazrati LN,. Functional anatomy of the basal ganglia: II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Brain Res Rev 1995; 20: 128-154.
42. Su PC, Ma Y, Fukuda M, et al. Metabolic changes following subthalamotomy for advanced Parkinson's disease. Ann Neurol 2001; 50: 514-520. (Pubitemid 32938896)
43. Trost M, Su S, Su P, et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage 2006; 31: 301-307. (Pubitemid 43728986)
44. Wang J, Ma Y, Huang Z, et al. Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease. J Neurol 2010; 257: 72-78.
45. Hilker R, Voges J, Weber T, et al. STN-DBS activates the target area in Parkinson disease: An FDG-PET study. Neurology 2008; 71: 708-713.
46. Pourfar M, Tang C, Lin T, et al. Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET. J Neurosurg 2009; 110: 1278-1282.
47. Mattis PJ, Tang CC, Ma Y, et al. Network correlates of the cognitive response to levodopa in Parkinson disease. Neurology 2011; 77: 858-865.
48. Feigin A, Fukuda M, Dhawan V, et al. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 2001; 57: 2083-2088. (Pubitemid 33126878)
49. Westin JE, Lindgren HS, Gardi J, et al. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci 2006; 26: 9448-9461. (Pubitemid 44396858)
50. Lindgren HS, Rylander D, Ohlin KE, et al. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav Brain Res 2007; 177: 150-159. (Pubitemid 46054185)
51. Ohlin KE, Francardo V, Lindgren HS, et al. Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Brain 2011; 134 (pt 8): 2339-2357.
52. Ohlin KE, Sebastianutto I, Adkins CE, et al. Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease. Neuroimage 2012; 61: 228-239.
53. Zaidel A, Arkadir D, Israel Z, Bergman H,. Akineto-rigid vs. tremor syndromes in Parkinsonism. Curr Opin Neurol 2009; 22: 387-393.
54. Helmich RC, Janssen MJ, Oyen WJ, et al. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. Ann Neurol 2011; 69: 269-281.
55. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994; 14: 783-801. (Pubitemid 24266530)
56. Habeck C, Krakauer JW, Ghez C, et al. A new approach to spatial covariance modeling of functional brain imaging data: ordinal trend analysis. Neural Comput 2005; 17: 1602-1645. (Pubitemid 40669913)
57. Bostan AC, Dum RP, Strick PL,. The basal ganglia communicate with the cerebellum. Proc Natl Acad Sci U S A 2010; 107: 8452-8456.
58. Hoshi E, Tremblay L, Feger J, et al. The cerebellum communicates with the basal ganglia. Nat Neurosci 2005; 8: 1491-1493. (Pubitemid 41573660)
59. Aarsland D, Kurz MW,. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010; 289: 18-22.
60. Huang C, Mattis P, Perrine K, et al. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008; 70 (16 pt 2): 1470-1477. (Pubitemid 351521942)
61. Hosokai Y, Nishio Y, Hirayama K, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 2009; 24: 854-862.
62. Pappata S, Santangelo G, Aarsland D, et al. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 2011; 77: 1357-1362.
63. Huang C, Mattis P, Tang C, et al. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007; 34: 714-723. (Pubitemid 44827754)
64. Carbon M, Ma Y, Barnes A, et al. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. Neuroimage 2004; 21: 1497-1507. (Pubitemid 38446574)
65. van Beilen M, Portman AT, Kiers HA, et al. Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: A clinical and FDOPA-PET study. Parkinsonism Relat Disord 2008; 14: 224-228.
66. Jokinen P, Bruck A, Aalto S, et al. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009; 15: 88-93.
67. Tang CC, Niethammer M, Gerber NJ, et al. Expression of a cognitive metabolic network in Parkinson's disease correlates with dopaminergic function in caudate nucleus. Neurology 2011; 76 (suppl 4): A489-A490.
68. Argyelan M, Carbon M, Ghilardi MF, et al. Dopaminergic suppression of brain deactivation responses during sequence learning. J Neurosci 2008; 28: 10687-10695.
69. Bezard E, Gross CE, Brotchie JM,. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 2003; 26: 215-221. (Pubitemid 36412004)
70. Appel-Cresswell S, de la Fuente-Fernandez R, Galley S, McKeown MJ,. Imaging of compensatory mechanisms in Parkinson's disease. Curr Opin Neurol 2010; 23: 407-412.
71. Moeller JR, Eidelberg D,. Divergent expression of regional metabolic topographies in Parkinson's disease and normal ageing. Brain 1997; 120 (pt 12): 2197-2206. (Pubitemid 28014596)
72. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
73. Schrag A, Ben-Shlomo Y, Quinn NP,. Prevalence of progressive supranuclear palsy and multiple system atrophy: A cross-sectional study. Lancet 1999; 354: 1771-1775.
74. Eckert T, Tang C, Ma Y, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord 2008; 23: 727-733.
75. Spetsieris PG, Ma Y, Dhawan V, Eidelberg D,. Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. Neuroimage 2009; 45: 1241-1252.
76. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: A double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011; 10: 309-319.
77. Pourfar MH, Tang CC, Mogilner AY, et al. Using imaging to identify psychogenic parkinsonism before deep brain stimulation surgery. J Neurosurg 2012; 116: 114-118.
78. Postuma RB, Gagnon JF, Montplaisir JY,. REM sleep behavior disorder: from dreams to neurodegeneration. Neurobiol Dis 2012; 46: 553-558.
79. Stiasny-Kolster K, Doerr Y, Moller JC, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005; 128 (pt 1): 126-137. (Pubitemid 40070527)
80. Albin RL, Koeppe RA, Chervin RD, et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000; 55: 1410-1412.
81. Poston KL, Tang CC, Eckert T, et al. Network correlates of disease severity in multiple system atrophy. Neurology 2012; 78: 1237-1244.
82. Maassen GH,. The standard error in the Jacobson and Truax Reliable Change Index: The classical approach to the assessment of reliable change. J Int Neuropsychol Soc 2004; 10: 888-893. (Pubitemid 39480819)